Does 950220.KQ pay a dividend?

The cached stock data on this page does not show a positive dividend yield for 950220.KQ. Dividend status can change, so verify the latest company filings before relying on income assumptions.

What does 950220.KQ stock do?

Clinical-stage biotechnology developer focused on long-acting human IL-7 (NT-I7) for oncology and infectious indications, generating negligible commercial revenue and operating at a net loss.

What is 950220.KQ stock's price target?

This cached page does not contain a precise model fair value for 950220.KQ.

Is 950220.KQ stock a buy?

The TradeMates model verdict for 950220.KQ is AVOID with an investment score of 29/100. Treat this as a model signal to review, not a personal buy recommendation.

Is 950220.KQ a good dividend stock?

950220.KQ is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.

950220.KQ (950220.KQ) Stock Analysis

Q: Is 950220.KQ stock a good investment?

The cached TradeMates AI model rates 950220.KQ as AVOID with an investment score of 29/100. The model assigns an AVOID rating due to extreme cash burn (-32.2B KRW FCF in 2025) relative to cash balance (38.8B KRW), implying urgent dilution risk within 15 months despite low P/B valuation. This is algorithmic model output, not personal investment advice.

Verdict: AVOID

Severe cash burn (~32B KRW/yr) against 38.8B KRW in cash creates urgent dilution risk before NT-I7 clinical trials yield commercial revenue.

Investment score: 29/100

The model assigns an AVOID rating due to extreme cash burn (-32.2B KRW FCF in 2025) relative to cash balance (38.8B KRW), implying urgent dilution risk within 15 months despite low P/B valuation.

View the full interactive analysis